ArticleTranslational cancer research2026
Pathological features and biomarkers of hepatocellular carcinoma: a bibliometric analysis from 2005 to 2025.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Erratum: Pathological features and biomarkers of hepatocellular carcinoma: a bibliometric analysis from 2005 to 2025.Translational cancer research · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) is a highly lethal and heterogeneous liver cancer in which pathology-derived features such as microvascular invasion (MVI) and histologic growth pattern critically shape prognosis and treatment selection. Over the past two decades, numerous serum, tissue and liquid-biopsy biomarkers have been proposed, but their development is fragmented and poorly integrated with pathology-based staging. We hypothesized that systematic bibliometric mapping of HCC pathology-related biomarker research would clarify global structures, hotspots and gaps along the pathway from mechanistic discovery to clinical translation. This study aims to map and quantify global research patterns in pathology-related biomarkers for HCC from 2005 to 2025. Methods: We performed a cross-sectional bibliometric study of HCC pathology-biomarker literature indexed in the Science Citation Index Expanded (SCIE) [Web of Science Core Collection (WoSCC)] between 1 January 2005 and 21 November 2025. English-language articles and reviews were retrieved using a combined pathology-biomarker-liver cancer topic search (TS). Descriptive indicators, collaboration networks, co-citation structures and keyword co-occurrence maps were generated using Bibliometrix (R), VOSviewer and CiteSpace. Results: A total of 2,907 publications were identified, with annual output rising from 9 in 2005 to 280 in 2025; nearly half of all papers appeared during 2021-2025. China contributed ~48% of articles, followed by the USA, Japan and Italy, while a small group of high-impact hepatology and oncology journals formed the core co-citation backbone. Keyword and burst analyses showed an evolution from classical serum markers and gene-expression studies toward multimodal biomarker systems integrating histopathology, tissue genomics, tumour microenvironment, immune infiltration, radiomics and liquid-biopsy platforms. Conclusions: Bibliometric mapping shows that pathology-related HCC biomarker research is rapidly expanding and shifting toward multimodal, pathology-informed systems, underscoring the need for validated integrative models and broader international collaboration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.